Irinotecan pharmacogenomics

Pharmacogenomics

Volumn 11, Issue 7, 2010, Pages 1003-1010

  Marsh, Sharon ^a   Hoskins, Janelle M ^a  

^a University of North Carolina   (United States)

Author keywords

ABCC2; irinotecan; pharmacogenomics; TDP1; toxicity; UGT1A1; XRCC1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; CISPLATIN; CYTOCHROME P450 3A4; DOXIFLURIDINE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCC2 GENE; ABCG2 GENE; AREA UNDER THE CURVE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSPORT; FEBRILE NEUTROPENIA; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GILBERT DISEASE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MARKER GENE; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; TDP1 GENE; UGT1A1 GENE; XRCC1 GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 77954380404     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.95     Document Type: Review

References (81)

1. Abang AM: The clinical pharmacology of topoisomerase I inhibitors. Semin. Hematol. 35(3 Suppl. 4), 13-21 (1998).
2. Rothenberg ML: The current status of irinotecan (CPT-11) in the United States. Ann. NY Acad. Sci. 803, 272-281 (1996).
3. Wall ME: Camptothecin and taxol: discovery to clinic. Med. Res. Rev. 18(5), 299-314 (1998).
4. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF: Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol. 23(1 Suppl. 3), 11-20 (1996).
5. Devore R 3rd, Johnson D, Crawford J, Dimery I, Eckardt J, Eckhardt SG: Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. Oncology (Williston Park) 12(8 Suppl. 6), 79-83 (1998).
6. Gershenson DM: Irinotecan in epithelial ovarian cancer. Oncology (Williston Park) 16(5 Suppl. 5), 29-31 (2002).
7. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
8. Hoff PM, Pazdur R: Progress in the development of novel treatments for colorectal cancer. Oncology 18(6), 705-708 (2004).
9. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21(5), 807-814 (2003).
10. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
11. Marsh S, McLeod HL: Cancer pharmacogenetics. Br. J. Cancer 90(1), 8-11 (2004).
12. Marsh S, McLeod HL: Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5(7), 835-843 (2004).
13. Gong QH, Cho JW, Huang T et al.: Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11(4), 357-368 (2001).
14. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60(5), 1189-1192 (2000).
15. Xu G, Zhang W, Ma MK, McLeod HL: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res. 8(8), 2605-2611 (2002).
16. Zhang W, Xu G, McLeod HL: Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl. Immunohistochem. Mol. Morphol. 10(4), 374-380 (2002).
17. Yano H, Kayukawa S, Iida S et al.: Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. Cancer Sci. 99(11), 2309-2314 (2008).
18. Marsh S, Xiao M, Yu J et al.: Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84(4), 661-668 (2004).
19. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J: Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin. Pharmacol. Ther. 76(6), 528-535 (2004).
20. Bellott R, Le Morvan V, Charasson V et al.: Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother. Pharmacol. 61(3), 481-488 (2008).
21. Wu MH, Chen P, Remo BF, Cook EH Jr, Das S, Dolan ME: Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics 13(7), 425-435 (2003).
22. Geshi E, Kimura T, Yoshimura M et al.: A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res. 28(9), 719-725 (2005).
23. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58(3), 468-472 (1998).
24. van der Bol JM, Mathijssen RH, Creemers GJ et al.: A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res. 16(2), 736-742 (2010).
25. Innocenti F, Ratain MJ: Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park) 17(5 Suppl. 5), 52-55 (2003).
26. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95(14), 8170-8174 (1998).
27. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24), 6921-6926 (2000).
28. Guillemette C, Millikan RC, Newman B, Housman DE: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 60(4), 950-956 (2000).
29. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A: Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9(5), 591-599 (1999).
30. Iyer L, Hall D, Das S et al.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65(5), 576-582 (1999).
31. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2(1), 43-47 (2002).
32. McLeod HL, Sargent DJ, Marsh S et al.: Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer; results from Intergroup Trial N9741. J. Clin. Oncol. DOI: 10.1200/JCO.2009.21. 7943 (2010) (Epub ahead of print).
33. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
34. Staessen JA, Kuznetsova T, Acceto R et al.; on behalf of the OASIS-HT Investigators: FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 6(7), 671-672 (2005).
35. Ratain MJ: From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin. Cancer Res. 12(6), 1658-1660 (2006).
36. Marsh S, van Rooij T: Challenges of incorporating pharmacogenomics into clinical practice. Gastrointest. Cancer Res. 3(5), 206-207 (2009).
37. Ratain MJ, Innocenti F: Individualizing dosing of irinotecan. Clin. Cancer Res. 16(2), 371-372 (2010).
38. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
39. Schulz C, Heinemann V, Schalhorn A et al.: UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J. Gastroenterol. 15(40), 5058-5066 (2009).
40. Toffoli G, Cecchin E, Gasparini G et al.: Genotype-driven Phase I study of irinotecan administered in combination with fuorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(5), 866-871 (2010).
41. Hazama S, Nagashima A, Kondo H et al.: Phase I study of irinotecan and doxifuridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci. 101(3), 722-727 (2010).
42. Premawardhena A, Fisher CA, Liu YT et al.: The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol. Dis. 31(1), 98-101 (2003).
43. Innocenti F, Undevia SD, Rosner GL et al.: Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 2006).
44. Sai K, Saeki M, Saito Y et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75(6), 501-515 (2004).
45. Hoskins JM, Mcleod HL: The move from pharmacokinetics to pharmacodynamics. Curr. Pharmacogenomics 4, 39-46 (2006).
46. de Jong FA, Scott-Horton TJ, Kroetz DL et al.: Irinotecan-induced diarrhea: functional signifcance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81(1), 42-49 (2007).
47. Han JY, Lim HS, Shin ES et al.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24(15), 2237-2244 (2006).
48. Takano M, Kato M, Yoshikawa T et al.: Clinical signifcance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76(5), 315-321 (2009).
49. Jada SR, Lim R, Wong CI et al.: Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98(9), 1461-1467 (2007).
50. Onoue M, Terada T, Kobayashi M et al.: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol. 14(2), 136-142 (2009).
51. Saito Y, Sai K, Maekawa K et al.: Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent infuence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab. Dispos. 37(2), 272-276 (2009).
52. Carlini LE, Meropol NJ, Bever J et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11(3), 1226-1236 (2005).
53. Hoskins JM, McLeod HL: UGT1A and irinotecan toxicity: keeping it in the family. J. Clin. Oncol. 27(15), 2419-2421 (2009).
54. Cecchin E, Innocenti F, D'Andrea M et al.: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fuorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15), 2457-2465 (2009).
55. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Update 6(2), 71-84 (2003).
56. Mathijssen RH, Marsh S, Karlsson MO et al.: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9(9), 3246-3253 (2003).
57. Lara PN Jr, Natale R, Crowley J et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27(15), 2530-2535 (2009).
58. Sai K, Kaniwa N, Itoda M et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13(12), 741-757 (2003).
59. Glimelius B, Garmo H, Berglund A et al.: Prediction of irinotecan and 5-fuorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. DOI: 10.1038/tpj.2010.10 (2010) (Epub ahead of print).
60. Han JY, Lim HS, Park YH, Lee SY, Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 63(1), 115-120 (2009).
61. Han JY, Lim HS, Yoo YK et al.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1), 138-147 (2007).
62. Fujita K, Nagashima F, Yamamoto W et al.: Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fuorouracil/leucovorin (FOLFIRI). Biol. Pharm. Bull. 31(11), 2137-2142 (2008).
63. Innocenti F, Kroetz DL, Schuetz E et al.: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27(16), 2604-2614 (2009).
64. Schellens JH, Maliepaard M, Scheper RJ et al.: Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann. NY Acad. Sci. 922, 188-194 (2000).
65. Candeil L, Gourdier I, Peyron D et al.: ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer 109(6), 848-854 (2004).
66. Imai Y, Nakane M, Kage K et al.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1(8), 611-616 (2002).
67. Sai K, Saito Y, Maekawa K et al.: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother. Pharmacol. 66(1), 95-105 (2009).
68. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61(24), 8654-8658 (2001).
69. Chatterjee S, Cheng MF, Trivedi D, Petzold SJ, Berger NA: Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-defcient cell lines. Cancer Commun. 1(6), 389-394 (1989).
70. Pouliot JJ, Yao KC, Robertson CA, Nash HA: Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 286(5439), 552-555 (1999).
71. Reid RJ, Fiorani P, Sugawara M, Bjornsti MA: CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc. Natl Acad. Sci. USA 96(20), 11440-11445 (1999).
72. Cusack JC Jr, Liu R, Houston M et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res. 61(9), 3535-3540 (2001).
73. Valente P, Arzani D, Cesario A, Margaritora S, Carbone E, Russo P: TNF increases camptothecin-induced apoptosis by inhibition of NF-kB. Eur. J. Cancer 39(10), 1468-1477 (2003).
74. Hoskins JM, Marcuello E, Altes A et al.: Irinotecan pharmacogenetics: infuence of pharmacodynamic genes. Clin. Cancer Res. 14(6), 1788-1796 (2008).
75. Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F: Pharmacodynamic genes do not infuence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics 10(7), 1139-1146 (2009).
76. Braun MS, Richman SD, Thompson L et al.: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol. 27(33), 5519-5528 (2009).
77. Artac M, Bozcuk H, Pehlivan S et al.: The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J. Cancer Res. Clin. Oncol. 136(6), 803-809 (2009).
78. Gold HT, Hall MJ, Blinder V, Schackman BR: Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 115(17), 3858-3867 (2009).
79. Raynal C, Pascussi JM, Leguelinel G et al.: Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer 9, 46 (2010).
80. Belanger AS, Tojcic J, Harvey M, Guillemette C: Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol. Biol. 11, 9 (2010).
81. Klein TE, Chang JT, Cho MK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 1(3), 167-170 (2001).